Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSB-9-W1 in metastatic colorectal cancer
NCT02249650Phase 1Completed
- Sponsor
- Taiwan Sunpan Biotechnology Development Co., Ltd.
- Start
- Jul 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TSB-9-W1 in metastatic colorectal cancer (mCRC), sponsored by Taiwan Sunpan Biotechnology Development Co., Ltd. Primary endpoints: Maximum Tolerated Dose up to 3 years, Dose Limiting Toxicities at 30 days and 1 more. Started Jul 2017; status: completed.
02
Drugs
TSB-9-W1
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02249650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249650.